Watson Settles with Barr Over Oxytrol

Law360, New York (October 28, 2009, 2:39 PM EDT) -- A unit of specialty pharmaceutical firm Watson Pharmaceuticals Inc. has struck a deal with Barr Pharmaceuticals Inc. that resolves patent litigation over Watson’s Oxytrol and grants Barr a license to eventually market a generic version of the overactive bladder treatment.

Watson Laboratories Inc. agreed to settle the infringement suit that it launched in October 2008 in the U.S. District Court for the District of Delaware after Barr filed an abbreviated new drug application seeking approval to make and sell a generic version of Oxytrol, a skin...
To view the full article, register now.

UK Financial Services

UK Financial Services

Read Our Latest UK Financial Services Coverage

Financial Services Law360 UK provides breaking news and analysis on the financial sector. Coverage includes UK and European Union policy, enforcement, and litigation involving banks, asset management firms, and other financial services organizations.